Evidence map›Paper›PMID 24492303›Full record

ArticlemAbs

Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency.

Louise Saul, Debra H Josephs, Keith Cutler, Andrew Bradwell, Panagiotis Karagiannis, Chris Selkirk, Hannah J Gould, Paul Jones, James F Spicer, Sophia N Karagiannis

Open access · goldAbstract readComparative Study
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. IgE Antibodies against Cancer: Efficacy and Safety.Antibodies (Basel, Switzerland) · 2020
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. IgE immunotherapy against cancer.Current topics in microbiology and immunology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 4 countries.

Louise SaulCutaneous Medicine and Immunotherapy; St. John's Institute of Dermatology; Division of Genetics and Molecular Medicine & NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London; London, UK; Research Oncology, Division of Cancer Studies; King's College London; Guy's Hospital; Great Maze Pond; London, UK.
Debra H JosephsCutaneous Medicine and Immunotherapy; St. John's Institute of Dermatology; Division of Genetics and Molecular Medicine & NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London; London, UK; Research Oncology, Division of Cancer Studies; King's College London; Guy's Hospital; Great Maze Pond; London, UK.
Keith CutlerPublic Health England; Porton Down; Salisbury, Wiltshire UK.
Andrew BradwellPublic Health England; Porton Down; Salisbury, Wiltshire UK.
Panagiotis KaragiannisCutaneous Medicine and Immunotherapy; St. John's Institute of Dermatology; Division of Genetics and Molecular Medicine & NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London; London, UK.
Chris SelkirkBiotherapeutics Development Unit; Cancer Research UK; South Mimms, Hertfordshire UK.
Hannah J GouldRandall Division of Cell and Molecular Biophysics & Division of Asthma; Allergy and Lung Biology, MRC and Asthma UK Centre for Allergic Mechanisms of Asthma, King's College London; London, UK.
Paul JonesDrug Development Office; Strategy and Research Funding; Cancer Research UK; London, UK.
James F SpicerResearch Oncology, Division of Cancer Studies; King's College London; Guy's Hospital; Great Maze Pond; London, UK.
Sophia N KaragiannisCutaneous Medicine and Immunotherapy; St. John's Institute of Dermatology; Division of Genetics and Molecular Medicine & NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London; London, UK.
King's College London · GBCancer Research UK · GBPublic Health England · GBSt. John's University · USGuy's Hospital · GBSt. Thomas Hospital · CAAsthma UK · GBInternational Drug Development · FRSalisbury NHS Foundation Trust · GB

Funding

Cancer Research UK C1519/A10331Cancer Research UK C30122/A11527Cancer Research UK C30122/A15774Chief Scientist OfficeMedical Research Council G1000758Medical Research Council G1100090
6 · The paper itself

Abstract

backgroundDue to genetic similarities with humans, primates of the macaque genus such as the cynomolgus monkey are often chosen as models for toxicology studies of antibody therapies. IgE therapeutics in development depend upon engagement with the FcεRI and FcεRII receptors on immune effector cells for their function. Only limited knowledge of the primate IgE immune system is available to inform the choice of models for mechanistic and safety evaluations.

methodsThe recognition of human IgE by peripheral blood lymphocytes from cynomolgus monkey and man was compared. We used effector cells from each species in ex vivo affinity, dose-response, antibody-receptor dissociation and potency assays.

resultsWe report cross-reactivity of human IgE Fc with cynomolgus monkey cells, and comparable binding kinetics to peripheral blood lymphocytes from both species. In competition and dissociation assays, however, human IgE dissociated faster from cynomolgus monkey compared with human effector cells. Differences in association and dissociation kinetics were reflected in effector cell potency assays of IgE-mediated target cell killing, with higher concentrations of human IgE needed to elicit effector response in the cynomolgus monkey system. Additionally, human IgE binding on immune effector cells yielded significantly different cytokine release profiles in each species.

conclusionThese data suggest that human IgE binds with different characteristics to human and cynomolgus monkey IgE effector cells. This is likely to affect the potency of IgE effector functions in these two species, and so has relevance for the selection of biologically-relevant model systems when designing pre-clinical toxicology and functional studies.

Indexed as

AnimalsAntibody AffinityCells, CulturedCytokinesCytotoxicity, ImmunologicHumansImmunoglobulin EImmunotherapyLectins, C-TypeLeukocytes, MononuclearMacaca fascicularisModels, AnimalProtein BindingReceptors, IgESpecies SpecificityCytokinesFCER1A protein, humanFCER2 protein, humanImmunoglobulin ELectins, C-TypeReceptors, IgEallergooncologyallergyantibody effector functionscancercross-species reactivitycynomolgus monkeyIgEIgE Fc receptorsnon-human primate

Identifiers

PMID24492303
PMCPMC3984339
OpenAlexW2035276582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.